Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;58(6):557-563.
doi: 10.1177/00185787231169455. Epub 2023 May 20.

Systematic Review of Piperacillin-Tazobactam and Vancomycin Y-Site Compatibility: Consideration of Concentration and Solution Variability

Emily M Ingalls  1 , Sarah Yost  2 , C Dustin Waters  3
Affiliations
Review

Systematic Review of Piperacillin-Tazobactam and Vancomycin Y-Site Compatibility: Consideration of Concentration and Solution Variability

Emily M Ingalls et al. Hosp Pharm. 2023 Dec.

Abstract

Simultaneous administration of vancomycin and piperacillin-tazobactam (VPT) poses significant challenges related to physical and chemical compatibility, as well as clinical practice. A systematic review of available literature related to VPT Y-site compatibility was performed. Data was collected from primary and tertiary sources. Seven articles were included in addition to one internal assessment and one review article and information from tertiary drug databases. The literature supports the simultaneous administration via Y-site of piperacillin-tazobactam 33.75 mg/mL in normal saline (NS) and vancomycin 4 to 8 mg/mL in NS. The same drug products at differing concentrations, diluents, storage conditions, or preparations outside of this recommendation should be considered incompatible.

Keywords: compatibility; piperacillin-tazobactam; vancomycin.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Wade J, Cooper M, Ragan R. Simulated y-site compatibility of vancomycin and piperacillin-tazobactam. Hosp Pharm. 2015;50(5):376-379. doi:10.1310/hpj5005-376 - DOI - PMC - PubMed
    1. Kufel WD, Miller CD, Johnson PR, et al.. Y-site incompatibility between premix concentrations of vancomycin and piperacillin-tazobactam: do current compatibility testing methodologies tell the whole story? Hosp Pharm. 2017;52(2):132-137. doi:10.1310/hpj5202-132 - DOI - PMC - PubMed
    1. Son A, Murphy NN, Wadsworth C, Bogorodskaya M, Hecker M. 248. Why so much vancomycin and piperacillin/tazobactam usage given known risks of nephrotoxicity. Open Forum Infect Dis, 2020;7(1):S123. doi: 10.1093/ofid/ofaa439.292 - DOI
    1. Peyko V, Smalley S, Cohen H. Prospective comparison of acute kidney injury during treatment with the combination of piperacillin-tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin. J Pharm Pract. 2017;30(2):209-213. doi:10.1177/0897190016628960 - DOI - PubMed
    1. Gomes DM, Smotherman C, Birch A, et al.. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy. 2014;34(7):662-669. doi:10.1002/phar.1428 - DOI - PubMed

LinkOut - more resources